EU regulator says AZ clot risk 'very rare' as nations battle virus surges
- But EMA chief Emer Cooke said no particular risk factor had been identified and the clots may be linked to an immune response to the vaccine.
THE HAGUE: The EU's medicines regulator said Wednesday that blood clots should be listed as a rare side effect of the AstraZeneca jab but the benefits continue to outweigh risks, as several countries battle fresh virus surges amid vaccine shortfalls.
A number of nations have suspended the use of AstraZeneca's vaccine for younger populations after it was earlier banned outright in several places over blood clot scares.
The United Kingdom on Wednesday said it will adopt new medical advice to offer most people under 30 an alternative to AstraZeneca if possible, after reporting 19 deaths from clots among people who received the shot.
The debate comes as countries from Germany to Ukraine and India face new waves of the virus that has now killed more than 2.8 million people.
Governments are scrambling to secure much-needed vaccine doses, with Australia the latest nation to complain of shortages that it blamed on EU export controls.
The European Medicines Agency (EMA) said Wednesday that blood clots should be listed as a "very rare" side effect, encouraging countries to continue its use.
The announcement came after the EMA examined 86 blood clotting cases, 18 of which were fatal, out of around 25 million people in Europe who received the AstraZeneca vaccine. Most of the cases were in women aged under 60.
But EMA chief Emer Cooke said no particular risk factor had been identified and the clots may be linked to an immune response to the vaccine.
"The benefits of the AstraZeneca vaccine in preventing Covid-19 overall outweigh the risk of side effects," she told a news conference.
"It is saving lives."
Comments
Comments are closed for this article.